公开(公告)号：US20180263967A1

公开(公告)日：2018-09-20

申请号：US15754934

申请日：2016-08-24

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Akira KAIEDA ,  Naoki ISHII ,  Hiroshi NARA ,  Masato YOSHIKAWA ,  Masaki DAINI

IPC: A61K31/454 ,  A61K31/4545 ,  A61K31/5377 ,  A61P29/00

CPC classification number: A61K31/454 ,  A61K31/4545 ,  A61K31/5377 ,  A61P29/00 ,  C07D413/12 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04

Abstract: The present invention provides a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of inflammatory disease and the like, and a medicament comprising the compound.The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

公开(公告)号：US20240317733A1

公开(公告)日：2024-09-26

申请号：US18449326

申请日：2023-08-14

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Shigemitsu MATSUMOTO ,  Yasushi HATTORI ,  Masashi TOYOFUKU ,  Shinji MORIMOTO ,  Masaki DAINI ,  Takuto KOJIMA ,  Tomohiro KAKU ,  Mitsuhiro ITO

IPC: C07D417/14 ,  C07D213/82 ,  C07D231/12 ,  C07D231/14 ,  C07D277/56 ,  C07D285/08 ,  C07D285/135 ,  C07D307/79 ,  C07D307/81 ,  C07D333/38 ,  C07D333/40 ,  C07D407/12 ,  C07D409/12 ,  C07D409/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12

CPC classification number: C07D417/14 ,  C07D213/82 ,  C07D231/12 ,  C07D231/14 ,  C07D277/56 ,  C07D285/08 ,  C07D285/135 ,  C07D307/79 ,  C07D307/81 ,  C07D333/38 ,  C07D333/40 ,  C07D407/12 ,  C07D409/12 ,  C07D409/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12

Abstract: The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubral pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula




wherein each symbol is as defined in the present specification, or a salt thereof.

公开(公告)号：US20220289679A1

公开(公告)日：2022-09-15

申请号：US17630442

申请日：2020-07-28

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Yuta TANAKA ,  Yuta TANAKA ,  Keiko KAKEGAWA ,  Takahito KASAHARA ,  Fumiaki KIKUCHI ,  Takeshi YAMAMOTO ,  Tomohiro OHASHI ,  Zenichi IKEDA ,  Florian PUENNER ,  Minoru NAKAMURA ,  Kazuaki TAKAMI ,  Masataka MURAKAMI ,  Masaki DAINI ,  Masaki SETO ,  Satoshi MIKAMI ,  Minoru SASAKI

IPC: C07D213/82 ,  C07D401/12 ,  C07D471/04 ,  C07D413/12 ,  C07D405/14 ,  C07D401/14 ,  C07D237/14 ,  C07D405/12

Abstract: The present invention provides a compound having a glucosylceramide synthase inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of lysosomal storage diseases (e.g., Gaucher's disease, Fabry's disease, GM1-gangliosidosis, GM2 activator deficiency, Tay-Sachs disease, Sandhoffs disease), neurodegenerative diseases (e.g., Parkinson's disease, Lewy body dementia, multiple-system atrophy) and the like.
The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.

公开(公告)号：US20200017444A1

公开(公告)日：2020-01-16

申请号：US16577449

申请日：2019-09-20

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Yuichi KAJITA ,  Satoshi MIKAMI ,  Yuhei MIYANOHANA ,  Tatsuki KOIKE ,  Masaki DAINI ,  Norio OYABU ,  Masaki OGINO ,  Kohei TAKEUCHI ,  Yoshiteru ITO ,  Norihito TOKUNAGA ,  Takahiro SUGIMOTO ,  Tohru MIYAZAKI ,  Tsuneo ODA ,  Yasutaka HOASHI ,  Yasushi HATTORI ,  Keisuke IMAMURA

IPC: C07D211/56 ,  A61P25/00 ,  C07D205/04 ,  C07D207/14 ,  C07D401/06 ,  C07D401/10 ,  C07D401/14 ,  C07D403/06 ,  C07D405/10 ,  C07D405/12 ,  C07D413/06 ,  C07D417/06 ,  C07D417/14 ,  C07D211/36 ,  C07D405/06

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：US20190300536A1

公开(公告)日：2019-10-03

申请号：US16366710

申请日：2019-03-27

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Yuya OGURO ,  Shigemitsu MATSUMOTO ,  Takeshi WAKABAYASHI ,  Norihito TOKUNAGA ,  Taku KAMEI ,  Mitsuhiro ITO ,  Satoshi MIKAMI ,  Masaki SETO ,  Shinji MORIMOTO ,  Shinji NAKAMURA ,  Sachie TAKASHIMA ,  Masataka MURAKAMI ,  Masaki DAINI ,  Makoto KAMATA ,  Minoru NAKAMURA ,  Yasufumi WADA ,  Hiroyuki KAKEI ,  Kazuaki TAKAMI ,  Taisuke TAWARAISHI ,  Jumpei AIDA ,  Kouichi IWANAGA ,  Satoshi YAMAMOTO

IPC: C07D487/04 ,  C07D471/04 ,  A61K9/20 ,  A61K9/48

Abstract: The present invention provides a heterocyclic compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and expected to be useful as an agent for the prophylaxis or treatment of major depression, bipolar disorder, migraine, pain, behavioral and psychological symptoms of dementia and the like.The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.

公开(公告)号：US20160311814A1

公开(公告)日：2016-10-27

申请号：US15203522

申请日：2016-07-06

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Shigemitsu MATSUMOTO ,  Yasushi HATTORI ,  Masashi TOYOFUKU ,  Shinji MORIMOTO ,  Masaki DAINI ,  Takuto KOJIMA ,  Tomohiro KAKU ,  Mitsuhiro ITO

IPC: C07D417/12 ,  C07D285/135 ,  C07D409/12 ,  C07D307/79 ,  C07D413/14 ,  C07D213/82 ,  C07D333/38 ,  C07D277/56 ,  C07D417/14 ,  C07D409/14 ,  C07D231/12 ,  C07D407/12

CPC classification number: C07D417/14 ,  C07D213/82 ,  C07D231/12 ,  C07D231/14 ,  C07D277/56 ,  C07D285/08 ,  C07D285/135 ,  C07D307/79 ,  C07D307/81 ,  C07D333/38 ,  C07D333/40 ,  C07D407/12 ,  C07D409/12 ,  C07D409/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12

Abstract: The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubural pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.

公开(公告)号：US20230357220A1

公开(公告)日：2023-11-09

申请号：US17999514

申请日：2021-05-20

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Tomoaki HASUI ,  Satoshi MIKAMI, JR. ,  Toru YAMASHITA ,  Shinji NAKAMURA ,  Shinji MORIMOTO ,  Toshihiro IMAEDA ,  Kazuaki TAKAMI ,  Masaki DAINI ,  Hiroyuki KAKEI ,  Minoru NAKAMURA ,  Fumie YAMAGUCHI ,  Chunxiang WANG ,  Sachie TAKASHIMA ,  Makoto KAMATA ,  Yuya OGURO ,  Shuhei IKEDA

IPC: C07D413/14 ,  C07D405/14 ,  C07D401/14

CPC classification number: C07D413/14 ,  C07D401/14 ,  C07D405/14

Abstract: Abstract: The present invention refers to compounds of formula (I). The present invention also relates to compounds of formula (I) for use as G Protein coupled Receptor 139 (GPR139) antagonists in methods of medical treatment of e.g. depression, Alzheimer’s disease, schizophrenia, drug addiction, sleep disorders, pain, and attention deficit hyperactivity disorder. Exemplary compounds are e.g. 3-((1H-pyrazol-4-yl)methyl)-6′-(phenyl)-2H-(1,2′-bipyridin)-2-one derivatives and related compounds. The present description discloses the synthesis and characterisation of exemplary compounds, pharmacological data thereof, as well as exemplary tablet formulations comprising the compounds of the invention (e.g. page 83 to page 110; examples 1 to 33; reference example 1; test examples 1 and 2; tables 1 to 4).

公开(公告)号：US20210179603A1

公开(公告)日：2021-06-17

申请号：US17176861

申请日：2021-02-16

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Shigemitsu MATSUMOTO ,  Yasushi HATTORI ,  Masashi TOYOFUKU ,  Shinji MORIMOTO ,  Masaki DAINI ,  Takuto KOJIMA ,  Tomohiro KAKU ,  Mitsuhiro ITO

IPC: C07D417/14 ,  C07D417/12 ,  C07D409/12 ,  C07D307/79 ,  C07D407/12 ,  C07D213/82 ,  C07D333/38 ,  C07D413/14 ,  C07D231/14 ,  C07D333/40 ,  C07D285/08 ,  C07D285/135 ,  C07D231/12 ,  C07D277/56 ,  C07D409/14 ,  C07D413/12 ,  C07D307/81

Abstract: The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubural pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.

公开(公告)号：US20190040010A1

公开(公告)日：2019-02-07

申请号：US16052967

申请日：2018-08-02

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Yuichi Kajita ,  Satoshi MIKAMI ,  Yuhei MIYANOHANA ,  Tatsuki KOIKE ,  Masaki DAINI ,  Norio OHYABU ,  Masaki OGINO ,  Kohei TAKEUCHI ,  Yoshiteru ITO ,  Norihito TOKUNAGA ,  Takahiro SUGIMOTO ,  Tohru MIYAZAKI ,  Tsuneo ODA ,  Yasutaka HOASHI ,  Yasushi HATTORI ,  Keisuke IMAMURA

IPC: C07D211/56 ,  C07D401/10 ,  C07D401/06 ,  C07D207/14 ,  C07D405/10 ,  C07D417/06 ,  C07D405/12 ,  C07D413/06 ,  C07D401/14 ,  C07D205/04 ,  C07D403/06 ,  C07D417/14 ,  A61P25/00

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：US20170001994A1

公开(公告)日：2017-01-05

申请号：US15270863

申请日：2016-09-20

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Shigemitsu MATSUMOTO ,  Yasushi HATTORI ,  Masashi TOYOFUKU ,  Shinji MORIMOTO ,  Masaki DAINI ,  Takuto KOJIMA ,  Tomohiro KAKU ,  Mitsuhiro ITO

IPC: C07D417/12 ,  C07D285/135 ,  C07D409/12 ,  C07D413/12 ,  C07D407/12 ,  C07D213/82 ,  C07D417/14 ,  C07D333/38 ,  C07D231/14 ,  C07D307/79

CPC classification number: C07D417/14 ,  C07D213/82 ,  C07D231/12 ,  C07D231/14 ,  C07D277/56 ,  C07D285/08 ,  C07D285/135 ,  C07D307/79 ,  C07D307/81 ,  C07D333/38 ,  C07D333/40 ,  C07D407/12 ,  C07D409/12 ,  C07D409/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12

Abstract: The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubural pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.

Abstract translation: 其中每个符号如本说明书中所定义，或其盐。